A novel predictor of XXXX patency before percutaneous intervention and in-hospital outcomes for @entity583 patients: serum @entity648 level.

@entity1 @entity583 @entity648 @entity1188 @entity299 @entity453
INTRODUCTION: Previous studies have reported a relationship between serum @entity648 levels and @entity453 ( @entity453 ). However, data are rare up to now regarding the relation of @entity648 levels with @entity1188 ( @entity1188 ) patency in the setting of @entity583 ( @entity583 ). Moreover, previous studies reported that increased @entity648 was related to impaired post-intervention coronary flow. To our knowledge, the association between serum total @entity648 (TB) levels and pre-primary percutaneous coronary intervention (PCI) with patency of @entity1188 flow in @entity583 @entity1 has not been investigated. AIM: To evaluate the association of TB with pre-primary PCI, coronary flow and in-hospital major adverse @entity299 (MACE) in @entity1 with @entity583 . MATERIAL AND METHODS: A total of 360 consecutive @entity1 with @entity583 (mean age = 61.4   13.7 years) admitted within 12 h from the time of symptom onset were enrolled. @entity1 were divided into 2 groups based on the serum TB levels. We defined normal flow as pre-PCI TIMI 3 flow, while impaired flow was defined as pre-PCI TIMI  <= 2 flow. RESULTS: Pre-PCI impaired flow was higher in the TB group than pre-PCI normal flow (p < 0.001). In-hospital mortality and MACE were significantly higher in the high TB group (p = 0.002, p < 0.001 respectively). In the receiver operating characteristic curve analysis, TB > 0.825 mg/dl predicted impaired @entity1188 flow before p-PCI with a sensitivity of 79% and specificity of 71%. CONCLUSIONS: The TB is an inexpensive and readily available marker for @entity583 @entity1 undergoing PCI. It can be used for risk stratification in this @entity1 population.
